alexa Serum Soluble CD25 and CD30 Levels as a Biomarker in Adult T-Cell Leukemia/Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | Open Access Journals
ISSN: 2329-8790
Journal of Hematology & Thromboembolic Diseases
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Serum Soluble CD25 and CD30 Levels as a Biomarker in Adult T-Cell Leukemia/Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Shigeki Takemoto1,2*
1Department of International Cooperation, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
2Clinical Laboratory, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
Corresponding Author : Dr. Shigeki Takemoto, M.D., Ph.D.
Chief of Clinical laboratory
National Hospital Organization Kumamoto Medical Center
1-5 Ninomaru, Kumamoto 860-0008, Japan
Tel: +81-(0)96-353-6501
Fax: +81-(0)96-325-2519
E-mail: [email protected]
Received December 23, 2014; Accepted January 14, 2015; Published January 25, 2015
Citation: Takemoto S (2015) Serum Soluble CD25 and CD30 Levels as a Biomarker in Adult T-Cell Leukemia/Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. J Hematol Thrombo Dis 3:182. doi:10.4172/2329-8790.1000182
Copyright: © 2015 Takemoto S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Hematology & Thromboembolic Diseases

Keywords
Soluble CD30 (sCD30); Adult T-cell leukemia/ lymphoma (ATL); Allogeneic hematopoietic stem cell transplantation (HSCT), Graft-versus-host disease (GVHD)
Short Commentary
Adult T-cell leukemia / lymphoma (ATL) is one of the incurable mature T-cell malignancies [1]. ATL patients are usually first treated with chemotherapy [2]. Recently, younger survivors after chemotherapy are candidates for allogeneic hematopoietic stem cell transplantation (HSCT) [3]. We compared the clinical value of soluble CD30 (sCD30) levels with soluble interleukin 2 receptor α chain (sCD25) levels in 24 ATL patients underwent HSCT at National Hospital Organization Kumamoto Medical Center [4]. The sera of the patients before conditioning therapy were preserved and levels of sCD30 and sCD25 were subsequently measured using sandwich enzyme-linked immunosorbent assay. In some patients, serial blood samples were taken during the course of treatment if they consented to the procedures. CD30 is a member of the tumor necrosis factor receptor superfamily [5]. The soluble form, sCD30, is cleaved by a disintegrin and metalloproteinase (ADAM)10 and/or ADAM17, while shedding of CD25 is dependent on matrix metalloproteinase-9 [6]. The levels of sCD30 as well as sCD25 are elevated in HTLV-1 carriers and highly elevated in ATL [5]. In univariate analysis of prognostic factor in patients underwent HSCT, both sCD25 (p=0.041) and sCD30 levels (p=0.0003) levels were significant predictor of overall survival in HSCT. Furthermore, sCD30 levels before the conditioning therapy turns out to predict more patients with early death (7 of 11) than were predicted by sCD25 levels (4 of 11) [4].
Regarding graft-versus-host disease (GVHD), Kanda et al. reported that the development of grade I-II acute GVHD was significantly associated with higher overall survival compared with the absence of acute GVHD [7]. Furthermore, occurrence of either grade I-II or grade III-IV acute GVHD was associated with lower disease-associated mortality compared with the absence of acute GVHD [7]. In our study, no acute GVHD or severe acute GVHD (grade III or IV) (n=10) was associated with unfavorable prognosis in contrast to the favorable prognosis associated with grade I and II (n=14) (hazard ratios=8.2, 95% confidence intervals 2.4–28, p=0.0007) [4]. Chen et al. compared the expression of CD30 on specific peripheral blood T-cell subsets and levels of sCD30 from patients with acute GVHD after HSCT and also analyzed the expression of CD30 in the biopsies of affected tissues from patients with intestinal acute GVHD [8]. Usually, both levels of soluble cytokine receptors are elevated temporally, suggesting successful treatment of GVHD [8]. However, in our two patients with severe acute GVHD, the sCD30 levels were elevated to 8 and 49 times at the peak of GVHD from the basal value after transplantation. Levels of sIL-2 were 4 and 7 times, respectively. In those cases, sCD30 levels were shown to surge rather than sCD25 after bone marrow transplantation. However, further analysis is required to reach the conclusion.
So far there is no application of sCD30 measurement to any diseases covered by insurance in Japan. However, it is thought that sCD30 is a useful biomarker to predict the risks involved with HSCT. This is the reason why the serial examination of sCD30 might be required for the success of ATL treatment.
References








Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11738
  • [From(publication date):
    February-2015 - Oct 17, 2017]
  • Breakdown by view type
  • HTML page views : 7912
  • PDF downloads :3826
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords